Green Cross Cell Obtains Patent Related to 'CAR-T Cell Therapy'
[Asia Economy Reporter Kum Boryeong] Green Cross Cell announced on the 20th that it has acquired a patent related to 'Mesothelin-specific chimeric antigen receptor and T cells expressing the same.'
Hot Picks Today
"Buy on Black Monday"... Japan's Nomura Forecasts 590,000 for Samsung, 4 Million for SK hynix
- "Plunged During the War, Now Surging Again"... The Real Reason Behind the 6% One-Day Silver Market Rally [Weekend Money]
- With Pop Stars Flocking to Korea, $1.7 Billion Concert Market Emerges... Korea Becomes a ‘Must-Visit Hub’ for Asia Tours
- "Samsung and Hynix Were Once for the Underachievers"... Hyundai Motor Employee's Lament
- "That? It's Already Stashed" Nightlife Scene Crosses the Line [ChwiYak Nation] ③
Green Cross Cell stated, "We have developed a CAR-T cell therapy, that is, T cells expressing a chimeric antigen receptor containing a human-derived mesothelin-specific antibody through this invention," and added, "It is planned to be developed as a treatment for solid tumors, especially mesothelioma, pancreatic cancer, lung cancer, ovarian cancer, and all solid tumors expressing mesothelin."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
